All Stories

  1. From Acute Infection to Chronic Risk: Reframing Pneumonia Outcomes through Long-Term Mortality Prediction

    Article • American Review of Respiratory Disease, March 2026, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  2. Corticosteroids in severe community-acquired pneumonia: friend, foe or both?

    Article • Pneumonia, February 2026, Springer Science + Business Media

    Dr CATIA CILLONIZ

  3. Transforming post-acute pneumonia management: risk stratification using machine learning

    Article • ERJ Open Research, January 2026, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  4. Nuevas perspectivas en la neumonía adquirida en la comunidad en el adulto

    Article • South Health, December 2025, Universidad Cientifica del Sur

    Dr CATIA CILLONIZ

  5. Corticosteroids and hospital-acquired pneumonia

    Article • Pneumonia, December 2025, Springer Science + Business Media

    Dr CATIA CILLONIZ

  6. The pneumonia challenge: time to end the global neglect

    Article • The Lancet Global Health, December 2025, Elsevier

    Dr CATIA CILLONIZ

  7. Immunosuppressed patients with COVID-19 pneumonia in ICU: clinical characteristics and factors influencing outcomes

    Article • Pneumonia, November 2025, Springer Science + Business Media

    Dr CATIA CILLONIZ

  8. Critical Challenges: Respiratory Infections in Immunocompromised ICU Patients

    Article • Seminars in Respiratory and Critical Care Medicine, November 2025, Thieme Publishing Group

    Dr CATIA CILLONIZ

  9. Pulse oximetry to optimise first-line care and save children’s lives: evidence from the AIRE project in West Africa

    Article • BMJ Global Health, November 2025, BMJ

    Dr CATIA CILLONIZ

  10. Why RSV Infection Matter in Older Adults? The Urgent Need for Vaccination

    Article • Archivos de Bronconeumología (English Edition), November 2025, Elsevier

    Dr CATIA CILLONIZ

  11. Pulmonary Infections in Patients with Human Immunodeficiency Virus Infection

    Article • Seminars in Respiratory and Critical Care Medicine, October 2025, Thieme Publishing Group

    Dr CATIA CILLONIZ

  12. Identifying predictors of treatment failure with community-acquired pneumonia: an update

    Article • Expert Review of Anti-infective Therapy, July 2025, Taylor & Francis

    Dr CATIA CILLONIZ

  13. Risk Factors and Outcomes Associated With Polymicrobial Infection in Community-Acquired Pneumonia

    Article • Archivos de Bronconeumología (English Edition), July 2025, Elsevier

    Dr CATIA CILLONIZ

  14. Inteligencia Artificial en la identificación de la Neumonía Pediátrica en Radiografías de Tórax

    Article • Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo, June 2025, Association Medical Corps of the National Hospital Almanzor Aguinaga Asenjo

    Dr CATIA CILLONIZ

  15. Infecciones por el virus respiratorio sincitial en los adultos

    Article • Medicina Clínica, April 2025, Elsevier

    Dr CATIA CILLONIZ

  16. Viral community-acquired pneumonia: what’s new since COVID-19 emerged?

    Article • Expert Review of Respiratory Medicine, March 2025, Taylor & Francis

    Dr CATIA CILLONIZ

  17. Coronavirus Disease 2019 and Emerging Lung Infections in the Immunocompromised Patient

    Article • Clinics in Chest Medicine, March 2025, Elsevier

    Dr CATIA CILLONIZ

  18. Adult vaccinations against respiratory infections

    Article • Expert Review of Anti-infective Therapy, January 2025, Taylor & Francis

    Dr CATIA CILLONIZ

  19. Healthcare worker views on antimicrobial resistance in chronic respiratory disease

    Article • Antimicrobial Resistance and Infection Control, January 2025, Springer Science + Business Media

    Dr CATIA CILLONIZ

  20. Mechanical power is not associated with mortality in COVID-19 mechanically ventilated patients

    Article • Annals of Intensive Care, January 2025, Elsevier

    Dr CATIA CILLONIZ

  21. World Pneumonia Day 2024: Fighting Pneumonia and Antimicrobial Resistance

    Article • American Review of Respiratory Disease, December 2024, American Thoracic Society

    Dr CATIA CILLONIZ

  22. Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia

    Article • CHEST Journal, October 2024, Elsevier

    Dr CATIA CILLONIZ

  23. Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia

    Article • Thorax, September 2024, BMJ

    Dr CATIA CILLONIZ

  24. Outcomes of corticosteroid therapy in patients with viral community-acquired pneumonia

    Article • Pneumonia, September 2024, Springer Science + Business Media

    Dr CATIA CILLONIZ

  25. Epidemiology, ventilation management and outcomes of COVID–19 ARDS patients versus patients with ARDS due to pneumonia in the Pre–COVID era

    Article • Respiratory Research, August 2024, Springer Science + Business Media

    Prof Dr Carlos R R Carvalho, Dr CATIA CILLONIZ

  26. A review of the value of point-of-care testing for community-acquired pneumonia

    Article • Expert Review of Molecular Diagnostics, August 2024, Taylor & Francis

    Dr CATIA CILLONIZ

  27. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia

    Article • Scientific Reports, June 2024, Springer Science + Business Media

    Dr CATIA CILLONIZ

  28. Diabetes Mellitus and Pneumococcal Pneumonia

    Article • Diagnostics, April 2024, MDPI AG

    Dr CATIA CILLONIZ

  29. The association of premorbid conditions with 6-month mortality in acutely admitted ICU patients over 80 years

    Article • Annals of Intensive Care, March 2024, Elsevier

    Dr CATIA CILLONIZ

  30. Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort

    Article • Critical Care, March 2024, Springer Science + Business Media

    Dr CATIA CILLONIZ

  31. Viral Pneumonia: From Influenza to COVID-19

    Article • Seminars in Respiratory and Critical Care Medicine, January 2024, Thieme Publishing Group

    Dr CATIA CILLONIZ

  32. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study

    Article • Microorganisms, November 2023, MDPI AG

    Dr CATIA CILLONIZ

  33. World Pneumonia Day 2023: the rising global threat of pneumonia and what we must do about it

    Article • European Respiratory Journal, November 2023, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  34. Clinical Outcomes of Critical COVID-19 in HIV-Infected Adults: A Propensity Score Matched Analysis

    Article • Archivos de Bronconeumología (English Edition), November 2023, Elsevier

    Dr CATIA CILLONIZ

  35. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review

    Article • Journal of Clinical Medicine, October 2023, MDPI AG

    Dr CATIA CILLONIZ

  36. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantStaphylococcus aureuspneumonia

    Article • European Respiratory Review, October 2023, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  37. Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?

    Article • Frontiers in Medicine, October 2023, Frontiers

    Dr CATIA CILLONIZ

  38. Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia

    Article • The Science of The Total Environment, October 2023, Elsevier

    Inmaculada Arostegui, Dr CATIA CILLONIZ

  39. Interventions to improve outcomes in community-acquired pneumonia

    Article • Expert Review of Anti-infective Therapy, September 2023, Taylor & Francis

    Dr CATIA CILLONIZ

  40. The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP)

    Article • Expert Opinion on Drug Metabolism & Toxicology, September 2023, Taylor & Francis

    Dr CATIA CILLONIZ

  41. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Article • Intensive Care Medicine, July 2023, Springer Science + Business Media

    Dr CATIA CILLONIZ

  42. World Pneumonia Day 2023: Reducing the impact of pneumonia in the Americas

    Article • Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo, June 2023, Association Medical Corps of the National Hospital Almanzor Aguinaga Asenjo

    Dr CATIA CILLONIZ

  43. A Novel Approach to Temperature Profiling in Relation to Clinical Outcomes in Oncological Patients with Neutropenia

    Article • American Review of Respiratory Disease, May 2023, American Thoracic Society

    Dr CATIA CILLONIZ

  44. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Article • Archivos de Bronconeumología (English Edition), April 2023, Elsevier

    Dr CATIA CILLONIZ

  45. Características clínicas y epidemiológicas de las muertes por dengue durante un brote en el norte del Perú

    Article • Revista Peruana de Medicina Experimental y Salud Pública, March 2023, Instituto Nacional de Salud (Peru)

    Dr CATIA CILLONIZ

  46. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report

    Article • Annals of the American Thoracic Society, March 2023, American Thoracic Society

    Dr CATIA CILLONIZ

  47. Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study

    Article • Journal of Infection, March 2023, Elsevier

    Dr CATIA CILLONIZ

  48. Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?

    Article • Archivos de Bronconeumología (English Edition), March 2023, Elsevier

    Dr CATIA CILLONIZ

  49. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain

    Article • Pulmonology, February 2023, Elsevier

    Dr CATIA CILLONIZ

  50. Advances in molecular diagnostic tests for community-acquired pneumonia

    Article • Minerva Respiratory Medicine, February 2023, Edizioni Minerva Medica

    Dr CATIA CILLONIZ

  51. Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia

    Article • Archivos de Bronconeumología (English Edition), February 2023, Elsevier

    Dr Pedro J Marcos, Dr CATIA CILLONIZ

  52. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia

    Article • CHEST Journal, January 2023, Elsevier

    Dr CATIA CILLONIZ

  53. Hyperglycemia in Acute Critically Ill COVID-19 Patients

    Article • Archivos de Bronconeumología (English Edition), January 2023, Elsevier

    Dr CATIA CILLONIZ

  54. Validation of IDSA/ATS Guidelines for ICU Admission in Adults Over 80 Years Old With Community-Acquired Pneumonia

    Article • Archivos de Bronconeumología (English Edition), January 2023, Elsevier

    Dr CATIA CILLONIZ

  55. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia

    Article • Journal of Infection, December 2022, Elsevier

    Dr CATIA CILLONIZ

  56. Host-targeted approaches to sepsis due to community-acquired pneumonia

    Article • EBioMedicine, December 2022, Elsevier

    Dr CATIA CILLONIZ

  57. Differences between sexes concerning COVID-19-related pneumonia

    Article • Panminerva Medica, December 2022, Edizioni Minerva Medica

    Giancarlo Garuti, Dr CATIA CILLONIZ

  58. Respiratory viruses: their importance and lessons learned from COVID-19

    Article • European Respiratory Review, October 2022, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  59. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia

    Article • CHEST Journal, October 2022, Elsevier

    Dr CATIA CILLONIZ

  60. Relationship between corticosteroid use and incidence of ventilator-associated pneumonia in COVID-19 patients: a retrospective multicenter study

    Article • Critical Care, September 2022, Springer Science + Business Media

    Dr CATIA CILLONIZ

  61. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Article • Intensive Care Medicine, June 2022, Springer Science + Business Media

    Dr CATIA CILLONIZ

  62. Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome

    Article • Archivos de Bronconeumología (English Edition), June 2022, Elsevier

    Dr CATIA CILLONIZ

  63. Aspiration pneumonia

    Article • Revista Española de Quimioterapia, April 2022, Sociedad Espanola de Quimioterapia

    Dr CATIA CILLONIZ

  64. Ceftaroline in severe community-acquired pneumonia

    Article • Revista Española de Quimioterapia, April 2022, Sociedad Espanola de Quimioterapia

    Dr CATIA CILLONIZ

  65. Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications

    Article • Revista Española de Quimioterapia, April 2022, Sociedad Espanola de Quimioterapia

    Dr CATIA CILLONIZ

  66. Biomarcadores biológicos en las enfermedades respiratorias

    Article • Archivos de Bronconeumología (English Edition), April 2022, Elsevier

    Dr CATIA CILLONIZ

  67. [Translated article] Biological Biomarkers in Respiratory Diseases

    Article • Archivos de Bronconeumología (English Edition), April 2022, Elsevier

    Dr CATIA CILLONIZ

  68. What's Next in Pneumonia?

    Article • Archivos de Bronconeumología (English Edition), March 2022, Elsevier

    Dr CATIA CILLONIZ

  69. Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis

    Article • Archivos de Bronconeumología (English Edition), March 2022, Elsevier

    Dr CATIA CILLONIZ

  70. Severe Infections Due to Respiratory Viruses

    Article • Seminars in Respiratory and Critical Care Medicine, February 2022, Thieme Publishing Group

    Dr CATIA CILLONIZ

  71. One-year mortality after ICU admission due to COVID-19 infection

    Article • Intensive Care Medicine, January 2022, Springer Science + Business Media

    Dr CATIA CILLONIZ

  72. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study

    Article • Critical Care, January 2022, Springer Science + Business Media

    Dr CATIA CILLONIZ

  73. Management of pneumonia in critically ill patients

    Article • BMJ, December 2021, BMJ

    Dr CATIA CILLONIZ

  74. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study

    Article • Critical Care, December 2021, Springer Science + Business Media

    Dr CATIA CILLONIZ

  75. COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital

    Article • Pneumon, November 2021, E.U. European Publishing

    Dr CATIA CILLONIZ

  76. Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis

    Article • European Journal of Clinical Microbiology & Infectious Diseases, November 2021, Springer Science + Business Media

    Dr CATIA CILLONIZ

  77. Management and outcomes in critically ill nonagenarian versus octogenarian patients

    Article • BMC Geriatrics, October 2021, Springer Science + Business Media

    Dr CATIA CILLONIZ

  78. The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

    Article • Critical Care, September 2021, Springer Science + Business Media

    Dr Jordi Riera, Dr CATIA CILLONIZ

  79. Outcomes of Critically ill Very old patients with Acute Respiratory Distress Syndrome and Community-Acquired Pneumonia

    Article • September 2021, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  80. Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis

    Article • September 2021, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  81. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia

    Article • September 2021, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  82. Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study

    Article • European Respiratory Journal, September 2021, European Respiratory Society (ERS)

    antoni Torres, Dr CATIA CILLONIZ

  83. Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial

    Article • American Review of Respiratory Disease, September 2021, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  84. Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study

    Article • Critical Care, July 2021, Springer Science + Business Media

    Dr Katarzyna L Kotfis, Dr Marlies Ostermann, Dr CATIA CILLONIZ

  85. Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study

    Article • Clinical Microbiology and Infection, July 2021, Elsevier

    Dr CATIA CILLONIZ

  86. Pulse oximetry is an essential tool that saves lives: a call for standardisation

    Article • European Respiratory Journal, June 2021, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  87. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

    Article • The Lancet Respiratory Medicine, June 2021, Elsevier

    MD Massimo Girardis, Dr CATIA CILLONIZ

  88. Provision of critical care for the elderly in Europe: a retrospective comparison of national healthcare frameworks in intensive care units

    Article • BMJ Open, June 2021, BMJ

    Dr CATIA CILLONIZ

  89. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort

    Article • Critical Care, May 2021, Springer Science + Business Media

    Dr CATIA CILLONIZ

  90. Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia

    Article • Annals of the American Thoracic Society, May 2021, American Thoracic Society

    Dr CATIA CILLONIZ

  91. The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011–2018

    Article • Clinical Infectious Diseases, April 2021, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  92. Pneumonia

    Article • Nature Reviews Disease Primers, April 2021, Springer Science + Business Media

    Dr CATIA CILLONIZ

  93. Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis

    Article • Open Forum Infectious Diseases, April 2021, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  94. Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain

    Article • The Lancet Regional Health - Europe, April 2021, Elsevier

    Dr CATIA CILLONIZ

  95. Frailty is associated with long-term outcome in patients with sepsis who are over 80 years old: results from an observational study in 241 European ICUs

    Article • Age and Ageing, March 2021, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  96. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia

    Article • Annals of the American Thoracic Society, February 2021, American Thoracic Society

    Dr CATIA CILLONIZ

  97. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study

    Article • Intensive Care Medicine, January 2021, Springer Science + Business Media

    Dr CATIA CILLONIZ

  98. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

    Article • CHEST Journal, January 2021, Elsevier

    Dr Pedro J Marcos, Dr CATIA CILLONIZ

  99. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

    Article • Clinical Microbiology and Infection, January 2021, Elsevier

    Dr CATIA CILLONIZ

  100. Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes

    Article • Journal of Infection, January 2021, Elsevier

    Dr CATIA CILLONIZ

  101. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia

    Article • Archivos de Bronconeumología (English Edition), January 2021, Elsevier

    Dr CATIA CILLONIZ

  102. Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience

    Article • Respiratory Medicine, October 2020, Elsevier

    Dr CATIA CILLONIZ

  103. PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community

    Article • September 2020, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  104. Awareness and Pneumonia knowledge: where to start educating?

    Article • September 2020, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  105. Methicillin-susceptible Staphylococcus aureus in Community-Acquired Pneumonia: Risk Factors and Outcomes

    Article • September 2020, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  106. Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease

    Article • Journal of Clinical Medicine, September 2020, MDPI AG

    Dr Adamantia Liapikou, Dr CATIA CILLONIZ

  107. SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities

    Article • Annals of the American Thoracic Society, September 2020, American Thoracic Society

    Dr CATIA CILLONIZ

  108. The importance of airway and lung microbiome in the critically ill

    Article • Critical Care, August 2020, Springer Science + Business Media

    Dr CATIA CILLONIZ

  109. Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019

    Article • Clinical Infectious Diseases, July 2020, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  110. Q Fever (Coxiella Burnetii)

    Article • Seminars in Respiratory and Critical Care Medicine, July 2020, Thieme Publishing Group

    Dr CATIA CILLONIZ

  111. Promoting the use of social networks in pneumonia

    Article • Pneumonia, May 2020, Springer Science + Business Media

    Dr CATIA CILLONIZ

  112. Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens

    Article • European Respiratory Journal, May 2020, European Respiratory Society (ERS)

    Dr Adamantia Liapikou, Dr CATIA CILLONIZ

  113. Advances in molecular diagnostic tests for pneumonia

    Article • Current Opinion in Pulmonary Medicine, May 2020, Wolters Kluwer Health

    Dr Adamantia Liapikou, Dr CATIA CILLONIZ

  114. Are Macrolides as Effective as Fluoroquinolones in Legionella Pneumonia? Yes, but…

    Article • Clinical Infectious Diseases, April 2020, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  115. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study

    Article • European Journal of Clinical Microbiology & Infectious Diseases, April 2020, Springer Science + Business Media

    Dr Pedro J Marcos, Dr CATIA CILLONIZ

  116. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain

    Article • International Journal of Antimicrobial Agents, April 2020, Elsevier

    Dr CATIA CILLONIZ

  117. Gender differences in community-acquired pneumonia

    Article • Minerva Medica, April 2020, Edizioni Minerva Medica

    Dr CATIA CILLONIZ

  118. Community-acquired pneumonia in critically ill very old patients: a growing problem

    Article • European Respiratory Review, February 2020, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  119. Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators

    Article • Medical Sciences, January 2020, MDPI AG

    Dr CATIA CILLONIZ

  120. Can Artificial Intelligence Improve the Management of Pneumonia

    Article • Journal of Clinical Medicine, January 2020, MDPI AG

    Dr CATIA CILLONIZ

  121. Programmed ‘disarming’ of the neutrophil proteome reduces the magnitude of inflammation

    Article • Nature Immunology, January 2020, Springer Science + Business Media

    Dr CATIA CILLONIZ

  122. A multicentre analysis of Nocardia pneumonia in Spain: 2010–2016

    Article • International Journal of Infectious Diseases, January 2020, Elsevier

    Dr CATIA CILLONIZ

  123. Non-invasive ventilation in palliative care: a systematic review

    Article • Minerva Medica, January 2020, Edizioni Minerva Medica

    Dr CATIA CILLONIZ

  124. Reply to Musher

    Article • The Journal of Infectious Diseases, December 2019, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  125. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning

    Article • European Respiratory Journal, December 2019, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  126. An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria

    Article • Current Opinion in Infectious Diseases, December 2019, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  127. The contribution of frailty, cognition, activity of daily life and comorbidities on outcome in acutely admitted patients over 80 years in European ICUs: the VIP2 study

    Article • Intensive Care Medicine, November 2019, Springer Science + Business Media

    Dr CATIA CILLONIZ

  128. New antibiotics for community acquired pneumonia

    Article • Expert Opinion on Emerging Drugs, October 2019, Taylor & Francis

    Dr Adamantia Liapikou, Dr CATIA CILLONIZ

  129. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients

    Article • Expert Review of Anti-infective Therapy, October 2019, Taylor & Francis

    Dr CATIA CILLONIZ

  130. Prevalence and risk factors of sepsis in very old patients with CAP

    Article • September 2019, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  131. Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia

    Article • Journal of Clinical Medicine, September 2019, MDPI AG

    Dr CATIA CILLONIZ

  132. Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?

    Article • Journal of Clinical Medicine, August 2019, MDPI AG

    Dr CATIA CILLONIZ

  133. Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia

    Article • Respirology, August 2019, Wiley

    Dr Pedro J Marcos, Muhammad Irfan, Dr CATIA CILLONIZ

  134. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis

    Article • BMC Infectious Diseases, August 2019, Springer Science + Business Media

    Jordi Carratalà, Dr CATIA CILLONIZ

  135. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia

    Article • Journal of Clinical Medicine, August 2019, MDPI AG

    Dr CATIA CILLONIZ

  136. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia

    Article • Journal of Clinical Medicine, July 2019, MDPI AG

    Dr Adamantia Liapikou, Dr CATIA CILLONIZ

  137. non invasive diagnosis of nosocomial pneumonia

    Article • Expert Review of Anti-infective Therapy, June 2019, Taylor & Francis

    Dr Adamantia Liapikou, Dr CATIA CILLONIZ

  138. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia

    Article • June 2019, MDPI AG

    Dr CATIA CILLONIZ

  139. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired pneumonia

    Article • June 2019, MDPI AG

    Dr CATIA CILLONIZ

  140. lymphopenia predicts mortality in patients with ICU pneumonia

    Article • Journal of Clinical Medicine, June 2019, MDPI AG

    Dr Adamantia Liapikou, Dr CATIA CILLONIZ

  141. Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49

    Article • Microorganisms, June 2019, MDPI AG

    Dr CATIA CILLONIZ

  142. Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults

    Article • Frontiers in Cellular and Infection Microbiology, March 2019, Frontiers

    Dr CATIA CILLONIZ

  143. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia

    Article • Critical Care, March 2019, Springer Science + Business Media

    Dr CATIA CILLONIZ

  144. PES Pathogens in Severe Community-Acquired Pneumonia

    Article • Microorganisms, February 2019, MDPI AG

    Dr CATIA CILLONIZ

  145. An international perspective on hospitalized patients with viral community-acquired pneumonia

    Article • European Journal of Internal Medicine, February 2019, Elsevier

    Dr Pedro J Marcos, Dr CATIA CILLONIZ, Muhammad Irfan

  146. Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia

    Article • Minerva Pneumologica, February 2019, Edizioni Minerva Medica

    Dr CATIA CILLONIZ

  147. Community-acquired pneumonia as an emergency condition

    Article • Current Opinion in Critical Care, December 2018, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  148. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients with Community-Acquired Pneumonia

    Article • CHEST Journal, November 2018, Elsevier

    Dr CATIA CILLONIZ

  149. Reply to Head and Keynan

    Article • Clinical Infectious Diseases, October 2018, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  150. Drugs that increase the risk of community-acquired pneumonia: a narrative review

    Article • Expert Opinion on Drug Safety, September 2018, Taylor & Francis

    Dr CATIA CILLONIZ, Dr Adamantia Liapikou, antoni Torres

  151. Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART

    Article • Current Infectious Disease Reports, September 2018, Springer Science + Business Media

    Dr CATIA CILLONIZ

  152. Clinical Approach to Community-acquired Pneumonia

    Article • Journal of Thoracic Imaging, September 2018, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  153. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study

    Article • Intensive Care Medicine, August 2018, Springer Science + Business Media

    Dr CATIA CILLONIZ

  154. Inflammatory response depends on time since onset of symptoms in pneumonia

    Article • American Review of Respiratory Disease, August 2018, American Thoracic Society

    Rosario Menéndez, Dr CATIA CILLONIZ

  155. MagicplexTM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults

    Article • July 2018, Cold Spring Harbor Laboratory Press

    Dr CATIA CILLONIZ

  156. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia

    Article • PLOS One, July 2018, PLOS

    Dr CATIA CILLONIZ

  157. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients

    Article • European Respiratory Journal, July 2018, European Respiratory Society (ERS)

    Dr Marcos I. Restrepo, Dr CATIA CILLONIZ, Dr Pedro J Marcos, Muhammad Irfan

  158. Community-acquired bacterial pneumonia in adult HIV-infected patients

    Article • Expert Review of Anti-infective Therapy, July 2018, Taylor & Francis

    Dr CATIA CILLONIZ, antoni Torres

  159. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease

    Article • June 2018, Springer Science + Business Media

    Dr CATIA CILLONIZ

  160. Community-acquired Pneumonia and Acute Respiratory Distress Syndrome

    Article • Clinical Pulmonary Medicine, May 2018, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  161. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging

    Article • Medical Sciences, April 2018, MDPI AG

    Dr CATIA CILLONIZ

  162. Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study

    Article • Clinical Infectious Diseases, April 2018, Oxford University Press (OUP)

    Dr CATIA CILLONIZ

  163. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

    Article • Respiratory Medicine, April 2018, Elsevier

    Dr CATIA CILLONIZ

  164. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis

    Article • Journal of Infection, April 2018, Elsevier

    Dr CATIA CILLONIZ

  165. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia

    Article • European Respiratory Journal, March 2018, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ, Dr Adamantia Liapikou

  166. Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients

    Article • European Respiratory Journal, February 2018, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  167. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients

    Article • PLOS One, January 2018, PLOS

    Dr CATIA CILLONIZ

  168. New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study

    Article • American Review of Respiratory Disease, November 2017, American Thoracic Society

    antoni Torres, Dr CATIA CILLONIZ

  169. Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress

    Article • Journal of Thoracic Disease, November 2017, AME Publishing Company

    MD MPhil Pouline van Oort, Dr CATIA CILLONIZ

  170. Has Mortality of Community-Acquired Pneumonia Really Reduced?

    Article • Clinical Pulmonary Medicine, November 2017, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  171. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia

    Article • Annals of Translational Medicine, November 2017, AME Publishing Company

    Dr CATIA CILLONIZ

  172. Adjuvant therapies in critical care: steroids in community-acquired pneumonia

    Article • Intensive Care Medicine, October 2017, Springer Science + Business Media

    Dr CATIA CILLONIZ

  173. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia

    Article • Expert Opinion on Investigational Drugs, October 2017, Taylor & Francis

    Dr Adamantia Liapikou, Dr CATIA CILLONIZ

  174. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality

    Article • EBioMedicine, October 2017, Elsevier

    Dr CATIA CILLONIZ

  175. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia

    Article • European Respiratory Journal, September 2017, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  176. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study

    Article • Vaccine, September 2017, Elsevier

    Dr CATIA CILLONIZ

  177. Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia

    Article • PLOS One, August 2017, PLOS

    Dr CATIA CILLONIZ

  178. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients

    Article • CHEST Journal, August 2017, Elsevier

    Dr CATIA CILLONIZ

  179. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial

    Article • PLOS One, June 2017, PLOS

    Dr CATIA CILLONIZ

  180. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia

    Article • CHEST Journal, June 2017, Elsevier

    Dr CATIA CILLONIZ

  181. Risk factors for community-acquired pneumonia in adults

    Article • Minerva Respiratory Medicine, June 2017, Edizioni Minerva Medica

    Dr CATIA CILLONIZ

  182. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia

    Article • Journal of Infection, May 2017, Elsevier

    Dr CATIA CILLONIZ

  183. Typical Presentation of Legionella pneumophila Community-Acquired Pneumonia

    Article • Revista Portuguesa de Pneumologia (English Edition), May 2017, Elsevier

    Dr CATIA CILLONIZ

  184. Research in community-acquired pneumonia: the next steps

    Article • Intensive Care Medicine, April 2017, Springer Science + Business Media

    Dr CATIA CILLONIZ

  185. Seasonality of pathogens causing community-acquired pneumonia

    Article • Respirology, January 2017, Wiley

    Dr CATIA CILLONIZ

  186. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns

    Article • International Journal of Molecular Sciences, December 2016, MDPI AG

    Dr CATIA CILLONIZ

  187. Laboratory diagnosis of pneumonia in the molecular age

    Article • European Respiratory Journal, November 2016, European Respiratory Society (ERS)

    antoni Torres, Dr CATIA CILLONIZ

  188. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Article • Critical Care, October 2016, Springer Science + Business Media

    Professor Francisco J García-Peñalvo, Dr CATIA CILLONIZ

  189. Clinical management of community acquired pneumonia in the elderly patient

    Article • Expert Review of Respiratory Medicine, October 2016, Taylor & Francis

    Dr CATIA CILLONIZ

  190. Community-Acquired Pneumonia 2000-2015: What is New?

    Article • Barcelona Respiratory Network, October 2016, Fundacao Barcelona Respiratory Network

    Dr CATIA CILLONIZ

  191. Response

    Article • CHEST Journal, September 2016, Elsevier

    Dr CATIA CILLONIZ

  192. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa

    Article • CHEST Journal, August 2016, Elsevier

    Dr CATIA CILLONIZ

  193. Community-acquired pneumonia related to intracellular pathogens

    Article • Intensive Care Medicine, June 2016, Springer Science + Business Media

    Dr CATIA CILLONIZ

  194. Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia

    Article • European Respiratory Journal, May 2016, European Respiratory Society (ERS)

    Dr JAVIER GARAU, antoni Torres, Dr CATIA CILLONIZ

  195. What is the clinical relevance of drug-resistant pneumococcus?

    Article • Current Opinion in Pulmonary Medicine, May 2016, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  196. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia

    Article • European Respiratory Journal, April 2016, European Respiratory Society (ERS)

    antoni Torres, Dr CATIA CILLONIZ, Dr Adamantia Liapikou

  197. Pneumococcal vaccination

    Article • Current Opinion in Infectious Diseases, April 2016, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  198. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis

    Article • Influenza and Other Respiratory Viruses, February 2016, Wiley

    Dr Allison McGeer, Kamran Lankarani, Dr CATIA CILLONIZ, Jordi Carratalà

  199. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis

    Article • Journal of Infection, February 2016, Elsevier

    Dr CATIA CILLONIZ

  200. Severe community-acquired pneumonia: Corticosteroids as adjunctive treatment to antibiotics

    Article • Community Acquired Infection, January 2016, Spring Media Publishing

    Dr CATIA CILLONIZ

  201. Bronchiectasis in rare pulmonary diseases: A case series

    Article • Community Acquired Infection, January 2016, Spring Media Publishing

    Dr CATIA CILLONIZ

  202. Bacteraemia in outpatients with community-acquired pneumonia

    Article • European Respiratory Journal, November 2015, European Respiratory Society (ERS)

    antoni Torres, Dr CATIA CILLONIZ

  203. Polymicrobial community-acquired pneumonia: An emerging entity

    Article • Respirology, October 2015, Wiley

    Dr CATIA CILLONIZ

  204. Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia

    Article • Annals of the American Thoracic Society, October 2015, American Thoracic Society

    Dr CATIA CILLONIZ

  205. Bacteraemia in outpatient with community-acquired pneumonia

    Article • September 2015, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  206. Ceftobiprole for the treatment of pneumonia: a European perspective

    Article • Drug Design Development and Therapy, August 2015, Dove Medical Press

    Dr CATIA CILLONIZ, Dr Adamantia Liapikou, antoni Torres

  207. Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series

    Article • Jornal Brasileiro de Pneumologia, August 2015, FapUNIFESP (SciELO)

    Dr CATIA CILLONIZ

  208. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients

    Article • Journal of Infection, July 2015, Elsevier

    Dr CATIA CILLONIZ

  209. New antimicrobial approaches to gram positive respiratory infections

    Article • Pulmonary Pharmacology & Therapeutics, June 2015, Elsevier

    Dr CATIA CILLONIZ

  210. Macrolide resistance and outcomes of patients with Streptococcus pneumoniae pneumonia.

    Article • American Review of Respiratory Disease, June 2015, American Thoracic Society

    Dr CATIA CILLONIZ, Dr Adamantia Liapikou

  211. Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia

    Article • Annals of the American Thoracic Society, February 2015, American Thoracic Society

    Dr CATIA CILLONIZ

  212. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis

    Article • European Respiratory Journal, January 2015, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ, antoni Torres

  213. Severe community-acquired pneumonia: Severity and management

    Article • Community Acquired Infection, January 2015, Medknow

    Dr CATIA CILLONIZ, Dr Adamantia Liapikou

  214. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update

    Article • Community Acquired Infection, January 2015, Medknow

    Dr CATIA CILLONIZ, antonello nicolini

  215. Clinical Management of Bacterial Pneumonia

    Article • January 2015, Springer Science + Business Media

    Dr CATIA CILLONIZ

  216. Viral infections

    Article • December 2014, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  217. Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia

    Article • PLOS One, November 2014, PLOS

    Dr CATIA CILLONIZ, Dr Peter Michael Keller

  218. Severity and outcomes of community acquired pneumonia in asthmatic patients

    Article • Respiratory Medicine, November 2014, Elsevier

    Dr CATIA CILLONIZ

  219. Predicting treatment failure in patients with community acquired pneumonia: a case-control study

    Article • July 2014, Springer Science + Business Media

    Dr CATIA CILLONIZ

  220. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data

    Article • The Lancet Respiratory Medicine, May 2014, Elsevier

    Dr Allison McGeer, Dr CATIA CILLONIZ, Kamran Lankarani, Jordi Carratalà

  221. Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature

    Article • Pneumonologia i Alergologia Polska, April 2014, VM Media SP. zo.o VM Group SK

    Dr CATIA CILLONIZ

  222. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study

    Article • Intensive Care Medicine, March 2014, Springer Science + Business Media

    Dr CATIA CILLONIZ

  223. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome

    Article • European Respiratory Journal, February 2014, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  224. IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia

    Article • Journal of Clinical Virology, February 2014, Elsevier

    Dr CATIA CILLONIZ

  225. Pneumococcal disease: Epidemiology and new vaccines

    Article • Community Acquired Infection, January 2014, Medknow

    Dr CATIA CILLONIZ

  226. Community-acquired viral pneumonia in human immunodeficiency virus infected patients

    Article • Community Acquired Infection, January 2014, Medknow

    Dr CATIA CILLONIZ

  227. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis

    Article • Respiratory Research, January 2014, Springer Science + Business Media

    Dr CATIA CILLONIZ, Professor Stefano Aliberti

  228. Predicting Community-Acquired Pneumonia Etiology: Response

    Article • CHEST Journal, December 2013, Elsevier

    Dr CATIA CILLONIZ

  229. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia

    Article • Respiratory Care, November 2013, Daedalus Enterprises

    Dr CATIA CILLONIZ

  230. IgM levels in plasma predict outcome in severe pandemic influenza

    Article • Journal of Clinical Virology, November 2013, Elsevier

    Dr CATIA CILLONIZ

  231. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study

    Article • Thorax, October 2013, BMJ

    Dr CATIA CILLONIZ

  232. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia

    Article • CHEST Journal, September 2013, Elsevier

    Dr CATIA CILLONIZ, Professor Stefano Aliberti

  233. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1

    Article • Thorax, June 2013, BMJ

    Dr CATIA CILLONIZ, Professor Stefano Aliberti

  234. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia

    Article • American Review of Respiratory Disease, June 2013, American Thoracic Society

    Dr CATIA CILLONIZ, Dr Jacobo Sellares

  235. Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia

    Article • CHEST Journal, March 2013, Elsevier

    Dr CATIA CILLONIZ

  236. Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza A (H1N1)

    Article • Journal of the American Geriatrics Society, March 2013, Wiley

    Dr CATIA CILLONIZ

  237. Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome

    Article • Respirology, January 2013, Wiley

    Dr CATIA CILLONIZ

  238. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia

    Article • Intensive Care Medicine, January 2013, Springer Science + Business Media

    Dr CATIA CILLONIZ

  239. Influenza A (H1N1) Pneumonia

    Article • Clinical Pulmonary Medicine, November 2012, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  240. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes

    Article • Clinical Microbiology and Infection, November 2012, Elsevier

    Dr CATIA CILLONIZ

  241. Invasive Pneumococcal Disease Today

    Article • Clinical Pulmonary Medicine, September 2012, Wolters Kluwer Health

    Dr CATIA CILLONIZ

  242. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia

    Article • Journal of Infection, September 2012, Elsevier

    Dr CATIA CILLONIZ

  243. Entendimento da mortalidade em pneumonia pneumocócica bacterêmica

    Article • Jornal Brasileiro de Pneumologia, August 2012, FapUNIFESP (SciELO)

    Dr CATIA CILLONIZ

  244. Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia

    Article • CHEST Journal, June 2012, Elsevier

    Dr CATIA CILLONIZ

  245. Pulmonary Complications Of Pneumococcal CAP: Incidence, Predictors, And Outcomes

    Article • May 2012, American Thoracic Society

    Dr CATIA CILLONIZ

  246. Corticosteroids In Community-Acquired Pneumonia: Therapeutic Reasons And Outcomes

    Article • May 2012, American Thoracic Society

    Dr CATIA CILLONIZ

  247. Influence Of Long-Term Use Of Inhaled Corticoids On The Development Of Pleural Effusion In Community Acquired Pneumonia

    Article • May 2012, American Thoracic Society

    Dr CATIA CILLONIZ, Dr Jacobo Sellares

  248. Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia

    Article • May 2012, American Thoracic Society

    Dr CATIA CILLONIZ

  249. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza

    Article • Journal of Infection, March 2012, Elsevier

    Dr CATIA CILLONIZ

  250. Community-acquired pneumonia in outpatients: aetiology and outcomes

    Article • European Respiratory Journal, January 2012, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  251. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients

    Article • International Journal of Infectious Diseases, December 2011, Elsevier

    Dr CATIA CILLONIZ

  252. CAP IN COPD PATIENTS

    Article • European Respiratory Journal, September 2011, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ, Dr Adamantia Liapikou

  253. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1

    Article • European Respiratory Journal, August 2011, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  254. First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain

    Article • Medicina Intensiva, May 2011, Elsevier

    Dr CATIA CILLONIZ

  255. Microbial aetiology of community-acquired pneumonia and its relation to severity

    Article • Thorax, January 2011, BMJ

    Dr CATIA CILLONIZ

  256. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis

    Article • Critical Care, January 2011, Springer Science + Business Media

    Dr CATIA CILLONIZ

  257. Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients

    Article • Critical Care, January 2011, Springer Science + Business Media

    Dr CATIA CILLONIZ

  258. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic

    Article • European Respiratory Journal, November 2010, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  259. Correction

    Article • Thorax, August 2010, BMJ

    Dr CATIA CILLONIZ

  260. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia

    Article • European Respiratory Journal, July 2010, European Respiratory Society (ERS)

    Dr CATIA CILLONIZ

  261. Severe Mixed Community Acquired Pneumoniae

    Article • May 2010, American Thoracic Society

    Dr CATIA CILLONIZ

  262. Community-acquired Pneumonia In Outpatients: Microbial Etiology

    Article • May 2010, American Thoracic Society

    Dr CATIA CILLONIZ

  263. INDICATION OF PLEURAL DRAINAGE IN PARAPNEUMONIC EFFUSION: ADHERENCE TO THE AMERICAN COLLEGE OF CHEST PHYSICIANS’ GUIDELINES

    Article • May 2010, American Thoracic Society

    Dr CATIA CILLONIZ

  264. PARAPNEUMONIC EFFUSIONS ACCORDING TO THE CLASSIFICATION OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS: CLINICAL CHARACTERISTICS

    Article • May 2010, American Thoracic Society

    Dr CATIA CILLONIZ, Dr Jacobo Sellares

  265. Healthcare-associated Pneumonia (HCAP): Clinical Features And Biomarkers

    Article • May 2010, American Thoracic Society

    Dr CATIA CILLONIZ

  266. Nursing home-acquired pneumonia: a 10 year single-centre experience

    Article • Thorax, April 2010, BMJ

    Dr CATIA CILLONIZ

  267. Impact of Smoking Habit on the Etiology of Community-Acquired Pneumonia (CAP).

    Article • April 2009, American Thoracic Society

    Dr CATIA CILLONIZ

  268. Community-Acquired Pneumonia: Etiology and Severity Scores.

    Article • April 2009, American Thoracic Society

    Dr CATIA CILLONIZ

  269. Complicated Pneumococcal Pneumonia in Adults.

    Article • April 2009, American Thoracic Society

    Dr CATIA CILLONIZ

  270. Severe community-acquired pneumonia

    Article • European Respiratory Society (ERS)

    Dr CATIA CILLONIZ